Relationship between serum osteocalcin,osteosclerosis protein,periosteum protein and osteoporosis in patients with schizo-phrenia
Objective To investigate the relationship between serum osteocalcin,osteosclerosis protein,periosteum protein and osteoporosis in patients with schizophrenia.Methods Ninety-eight patients with schizo-phrenia diagnosed and treated in Ningbo Psychiatric Hospital from January 2022 to January 2023 were analyzed retrospectively.According to bone mineral density,they were divided into normal bone mass group(34 cases),reduced bone mass group(23 cases)and osteoporosis group(41 cases).The levels of serum osteocalcin,osteosclerosis protein and periosteum protein in all groups were compared.Pearson correlation was conducted to analyze the correlation between serum osteocalcin,osteossclerotin and periosteum protein and osteoporosis in schizophrenia patients.Multivariate logistic regression was used to analyze the relationship between serum indexes and schizophrenia complicated with osteoporosis.Results The levels of serum osteocalcin,osteosclerosis protein and periosteum protein among patients with different bone mineral density were significantly different(all P＜0.05),of which,the reduced bone mass group and osteoporosis group had significantly higher levels than the normal bone mass group(all P＜0.05),with those in the osteoporosis group higher than the reduced bone mass group(all P＜0.05).Serum osteocalcin,osteosclerosis protein and periosteum protein were positively correlated with osteoporosis in schizophrenia patients(r=0.498,0.387,0.265,P=0.012,0.023,0.031,respectively).Multiple linear regression analysis showed that serum levels of osteocalcin,osteosclerosis protein and periosteum protein were independent risk factors for osteoporosis in patients with schizophrenia(OR=2.563,1.003,2.198,all P＜0.05).Conclusion Serum levels of osteocalcin,osteosclerosis protein and periosteum protein are positively correlated with bone mineral density in patients with schizophrenia,and are independent risk factors for osteoporosis in patients with schizophrenia.
万方数据
维普
